^
Contact us to learn more about
our Premium Content: News alerts, weekly reports and conference plannersDRUG:
KAN571
i
Other names: KAN571, KAN0441571C
Contact us to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Company:
Kancera, Karolinska Institute
Drug class:
ROR1 inhibitor
Related drugs:
almost3years
Predicting ROR1/BCL2 combination targeted therapy of small cell carcinoma of the lung. (PubMed, Cell Death Dis)
Synergy as defined by a combination index of <1 via the Chou-Talalay method between KAN0441571C and venetoclax was demonstrated in 8 SCLC cell lines. We have shown that ROR1 inhibition is synergistic with BCL2 inhibition in SCLC models and shows promise as a novel therapeutic target in SCLC.
Journal • IO biomarker
|
BCL2 (B-cell CLL/lymphoma 2) • ROR1 (Receptor Tyrosine Kinase Like Orphan Receptor 1)
|
BCL2 expression
|
Venclexta (venetoclax) • KAN571
over3years
[VIRTUAL] Predicting ROR1/BCL2 Combination Targeted Therapy of Small Cell Carcinoma of the Lung (IASLC-WCLC 2020)
Synergy as defined by a combination index of <1 via the Chou-Talalay method between KAN0441571C and venetoclax was demonstrated in all 8 SCLC cell lines. Conclusion We have demonstrated that ROR1 inhibition is synergistic with BCL2 inhibition in SCLC models and shows promise as a novel therapeutic target in SCLC.
IO biomarker
|
BCL2 (B-cell CLL/lymphoma 2) • ROR1 (Receptor Tyrosine Kinase Like Orphan Receptor 1)
|
BCL2 expression
|
Venclexta (venetoclax) • KAN571
Share via
